The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...

Johnson & Johnson (J&J) and Protagonist Therapeutics’ investigational oral peptide icotrokinra (JNJ-2113) has been associated ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...

Changes in the healthcare world are likely to limit opportunities for young researchers, especially women.Three leaders in ...

BeiGene has announced that its Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a ...

Private equity firm Apiary Capital has completed its investment into life sciences performance marketing and specialist ...

Gene therapy has the potential to change lives, slowing or stopping disease progression or even correcting symptoms entirely, ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

Tiziana Life Sciences has announced promising results from an open-label study of its investigational multiple sclerosis (MS) ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...